GSK Confirms $2.2 Billion Settlement for US Zantac Lawsuit

2 min read | October 10, 2024 04:05 AM PDT | By Team Kalkine Media

Google News:

GSK Confirms $2.2 Billion Settlement for US Zantac Lawsuit — Image source: Shutterstock

Recent News

Is Pitney Bowes Still Hiding Value After Its Rally?

What’s Driving Unity Bancorp Climb To New Highs?

Why United Parcel Service Is Back on The Market Radar?

Why Is Halliburton Facing Fresh Market Pressure?

Make Kalkine Media
My Trusted Source

Highlights:

GSK PLC has reached a settlement agreement of up to $2.2 billion to resolve approximately 80,000 lawsuits related to its heartburn medication Zantac.
The settlement will address 93% of state court cases, with completion anticipated by mid-2025, while the company also plans to pay $70 million to settle a claim concerning a carcinogen found in the drug.
The financial implications include a £1.8 billion charge in the third-quarter 2024 results, which will help clarify legal uncertainties surrounding ongoing litigation.

GSK PLC {NYSE:GSK} has announced a significant settlement agreement amounting to up to $2.2 billion to resolve approximately 80,000 lawsuits filed in the United States concerning its heartburn medication, Zantac, also known as ranitidine. The lawsuits allege a link between the drug and cancer; however, GSK maintains that there is no evidence supporting this claim and has not admitted liability in these matters.

The settlement aims to resolve around 93% of the state court cases related to Zantac, with the completion of the agreement projected by mid-2025. Additionally, GSK will allocate $70 million to settle a claim from Valisure, a laboratory that raised concerns regarding a carcinogen associated with the medication.

Funding for these settlements will be sourced from GSK's existing resources, and the company has confirmed that its commitment to research and development will remain unchanged. A notable impact of this settlement will be a charge of approximately £1.8 billion reflected in the company’s third-quarter 2024 results. This charge is anticipated to be partially offset by reduced legal costs, thereby alleviating significant financial uncertainties tied to the ongoing litigation.

In response to the settlement, Deutsche Bank noted a renewed outlook for GSK, indicating that the company has become more appealing to stakeholders. The bank emphasized that the resolution of over 90% of the remaining state cases presents a positive development amid previously challenging valuations for GSK. Following this news, the company's shares closed at 1,458p, with Deutsche Bank highlighting a rating that suggests potential upward movement for the stock.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.